Glucagon tests are often performed to test the hypothalamic-pituitary axis and are not often associated with any signi¢cant complications. This case report in the Lancet describes a 43-year-old male with recently diagnosed type 2 diabetes mellitus and mild hypertension who developed life-threatening complications after having a glucagon test. The dynamic function test was performed to determine whether his diabetes was caused by a secretary defect of insulin and to assess his current treatment regime. 12 h later he presented to the emergency department with dyspnoea and haemoptysis. He had a raised white cell count with neutrophilia, a signi¢cant lactic acidosis and a creatinine of 268 mmol/L. He was transferred to ICU where he deteriorated, developing hypotension, anuric renal failure, rhabdomyolysis and widespread lung in¢ltrates. He later developed signi¢cant hypertension and phaeochromocytoma was considered in the di¡erential diagnosis. A mass was seen on CT scanning and elevated plasma catecholamines con¢rmed the diagnosis.
In this case the glucagon test precipitated a catecholamine crisis. Interestingly, the glucagon test was used in the past as a provocative test for the diagnosis of phaeochromocytoma, but abandoned because of the associated dangers. The validity of the glucagon test for determining b-cell function is also controversial, and it is debatable whether it was a necessary investigation in this patient.
The severe lactic acidosis seen at presentation was caused by the metabolic and vascular e¡ects of catecholamines. Furthermore his primary symptoms of hyperglycaemia could have been caused by the phaeochromocytoma. We are not told whether the patient had any persistent problems with glycaemic control after the removal of the phaeochromocytoma. However we do know that the patient was discharged, minus one adrenal tumour, after 3 whole months in hospital!
The case serves as a good reminder of some of the potential clinical complications in dynamic function testing. The authors suggest that it is prudent to be aware of the signs leading to a catecholamine crisis in a lean diabetic and hypertensive patient undergoing a glucagon test. However it may be a little too late at this stage. Such complications could be totally prevented by screening hypertensive diabetics for phaeochromocytoma prior to testing with glucagon. Lang et al. show that the genetic and pharmacological inhibition of Asm in mouse hepatocytes prevents Cu 2 þ induced cell death. Asm inhibition also protects rats with Wilson's disease from liver ¢brosis and hepatic failure. Furthermore patients with Wilson's disease show consitituively increased Asm activity in plasma, indicating that the mechanisms in the animal models are applicable to humans.
Lang et al. also demonstrate that ceramide release results in the exposure of phosphatidylserine on the cell surface of erthyrocytes, marking the cells for clearance by phagocytes. This provides a previously unrecognised mechanism for anaemia in Wilson's disease. However anaemia is a rare complication in Wilson's disease and the authors make no attempt to explain why many patients appear to be protected from such erythrocyte depletion.
The study provides an insight into Cu 2 þ mediated cell death in Wilson's disease and identi¢es Asm as a crucial component. Lang et al. hypothesise that pharmacological interference with Asm and ceramide could prevent liver cirrhosis and anaemia. This however remains to be seen.
As biochemists we may associate Asm with NiemannPick disease, the lipid storage disorder that results from a de¢ciency of Asm. One could therefore assume that patients with Niemann-Pick disease are totally protected from Cu 2 þ induced heptocellular damage. Any case report of Niemann-Pick disease with concomitant Wilson's disease induced liver damage would therefore be of great interest. 
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